The Fred Hollows Foundation and the Australian Council for International Development (ACFID) are taking the lead in a campaign calling on the Australian Government to invest in healthcare in the Indo-Pacific. Read more
Mark Zuckerberg teases new EssilorLuxottica smart glasses with neural interface
Facebook founder Mr Mark Zuckerberg has travelled to Milan to meet with EssilorLuxottica chairman Mr Leonardo Del Vecchio where he hinted at a new smart glasses project featuring a neural interface wristband. Read more
Smart glasses from EssilorLuxottica and Meta win prestigious design competitions
Ray-Ban Stories, the smart glasses from EssilorLuxottica and Facebook’s parent company Meta, has claimed awards from two renowned design competitions: the iF Design and Red Dot Design awards. Read more
SightGlass Vision specs’ two-year data demonstrates myopia control efficacy
Spectacles that use SightGlass Vision’s trademarked Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children, based on 24-month interim data from its pivotal multisite clinical study. Read more
Bausch + Lomb eyes AU$1.2 billion in IPO
Ophthalmic giant Bausch + Lomb (B+L), which is being spun-off from its parent as a pure-play eye health company, has filed to raise up to US$840 million (AU$1.2 billion) in an initial public offering (IPO). Read more
EssilorLuxottica makes play for eyeglass cases and packaging business
As it took 100% control of GrandVision and offloaded 177 stores this month, EssilorLuxottica announced a leadership reshuffle for the optical retail giant, including a new CEO. Read more
New five-year data for MIGS device
Half a decade of data on the second generation iStent inject has shown a significant reduction in intraocular pressure (IOP) and medication burden in glaucoma patients. Read more
Study confirms vision problems linked to erectile dysfunction medications
The risk of developing one of three serious eye conditions increases by 85% for regular users of common erectile dysfunction (ED) medications such as Viagra, Cialis, Levitra and Stendra, new research has found. Read more
Glaukos commences trials for its third-generation keratoconus therapy
Glaukos has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Read more
Beovu obtains DME indication in Europe
The European Commission (EC) has approved anti-VEGF therapy Beovu (brolucizumab) 6 mg for diabetic macular edema (DME), marking the therapy’s second indication in the bloc. Read more